Skip to main content

A comparative study of Tissue Inhibitor of Metalloproteinases-1 levels in plasma and tumour tissue from patients with primary breast cancer and in plasma from patients with metastatic breast cancer

Buy Article:

$48.00 plus tax (Refund Policy)

Abstract:

Background.

Levels of tissue inhibitor of metalloproteinases-1 (TIMP-1) have been investigated in tumour tissue and blood and are associated with prognosis in patients with primary breast cancer. Here we investigated the correlation between TIMP-1 levels in tumour tissue and in blood plasma to evaluate whether TIMP-1 in plasma is a surrogate marker for the TIMP-1 concentration in the primary tumour. Furthermore, to assess whether increased TIMP-1 levels in plasma could be indicators of tumour progression we compared these levels in primary breast cancer patients with levels in patients with advanced breast cancer. Methods.

Tumour tissue and preoperatively collected plasma samples from 96 patients with primary breast cancer (stage M0) were examined. In addition, from 46 patients with advanced breast cancer (stage M1), plasma samples were included and levels of TIMP-1 in these samples were compared with plasma levels of TIMP-1 in primary breast cancer patients. TIMP-1 levels were measured by an ELISA developed in our laboratory. Results.

TIMP-1 levels in plasma (median 81.5 ng/mL, range 41.9–174.9) and tumour tissue (median 25.4 ng/mg of total protein, range 0 – 110.2 ng/mg of total protein) from primary breast cancer patients were not correlated (r=0.05, p=0.6). Plasma levels of TIMP-1 in primary breast cancer patients (median 81.5 ng/mL, range 41.9–174.9) were significantly lower than levels in patients with advanced breast cancer (median 108.7 ng/mL, range 59.7–560.7; p<0.0001). Conclusions.

Counter to expectation, TIMP-1 levels in plasma and tissue are not correlated suggesting that TIMP-1 release into the blood might be controlled by an active mechanism. The significant difference in plasma TIMP-1 levels in patients with primary and metastatic breast cancer, respectively, points to plasma TIMP-1 as a potential future candidate marker for prediction of tumour progression and for monitoring metastatic tumour burden in breast cancer patients.

Document Type: Abstract

DOI: http://dx.doi.org/10.1111/j.1600-0463.2008.001165_7.x

Affiliations: 1: University Medical Center Hamburg-Eppendorf, Gynækologisk afd., Martinistrasse 52, D-20246 Hamburg, Tyskland 2: Finsenlaboratoriet, Rigshospitalet, afd. 37-3-5, Copenhagen Biocenter, Ole Maaløes Vej 5, 2200 København N 3: University Medical Center Hamburg-Eppendorf, Institut for Tumorbiologi, Martinistrasse 52, D-20246 Hamburg, Tyskland 4: Københavns Universitet, Det Biovidenskabelige Fakultet for Fødevarer, Veterinærmedicin og Naturressourcer, Institut for Veterinær Patobiologi, Ridebanevej 9, 1870 Frb. C, Danmark

Publication date: May 1, 2008

mksg/apm/2008/00000116/00000005/art00017
dcterms_title,dcterms_description,pub_keyword
6
5
20
40
5

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more